nsc 65346 profile

sangivamycin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

nsc 65346 is involved in 1 pathway(s), involving a total of 3 unique proteins and 3 unique compounds

ID Source	ID
PubMed CID	14978
CHEMBL ID	101892
CHEBI ID	85997
SCHEMBL ID	195540
MeSH ID	M0047407

Synonym
BIDD:GT0419
antibiotic b-14437
7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide, 4-amino-7-beta-d-ribofuranosyl-
b-14437
brn 0626355
4-amino-7-beta-d-ribofuranosyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide
chebi:85997 ,
CHEMBL101892 ,
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide
4-amino-7-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid amide
cid_5153
bdbm50049820
4-amino-5-carboxamide-7-(d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid amide
sangivamycin
nsc-65346
7-deazaadenosine-7-carboxamide
7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-.beta.-d-ribofuranosyl-
sanzivamycin
sangivamycin, hydrochloride
4-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
7-deaza-7-carbamoyladenosine
SGV ,
4-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
unii-l8yq8z3t9t
l8yq8z3t9t ,
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide
OBZJZDHRXBKKTJ-JTFADIMSSA-N
SCHEMBL195540
3NYN
7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide, 4-amino-7-.beta.-d-ribofuranosyl-
4-amino-7-.beta.-d-ribofuranosyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide
4-amino-7-beta-d-ribofuranosyl-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide
J-011802
4-amino-7-(beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide
Q27158840
MS-24486
HY-118384
DTXSID601028118
CS-0065802
AKOS040759898

Role	Description
protein kinase inhibitor	An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of protein kinases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
nucleoside analogue	An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
sangivamycin biosynthesis	3	3

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A1	Rattus norvegicus (Norway rat)	IC50 (µMol)	2,137,960.0000	0.0002	0.5521	10.0000	AID34006
Adenosine receptor A3	Rattus norvegicus (Norway rat)	IC50 (µMol)	2,137,960.0000	0.0007	0.0374	0.0957	AID34006
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	IC50 (µMol)	2,137,960.0000	0.0024	0.6816	9.0000	AID34006
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	IC50 (µMol)	2,137,960.0000	0.0012	0.4828	9.0000	AID34006
Adenosine kinase	Homo sapiens (human)	IC50 (µMol)	1,066,402.7350	0.0005	0.6052	10.0000	AID33985; AID33990; AID33993; AID34006
Adenosine kinase	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	16.5000	1.2000	3.8333	8.0000	AID1596006
Rhodopsin kinase GRK1	Homo sapiens (human)	Ki	0.1800	0.1800	0.1800	0.1800	AID357074
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0001	0.5135	7.0000	AID1636908
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, G protein-coupled receptor kinase 6	Homo sapiens (human)	Kd	1.0000	1.0000	1.0000	1.0000	AID977611
Heat shock cognate 71 kDa protein	Homo sapiens (human)	Kd	3.2680	0.2600	3.0511	7.0000	AID1310291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G1/S transition of mitotic cell cycle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
mRNA splicing, via spliceosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
kidney development	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein folding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein import into nucleus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to unfolded protein	Heat shock cognate 71 kDa protein	Homo sapiens (human)
skeletal muscle tissue development	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cellular response to starvation	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to xenobiotic stimulus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to nickel cation	Heat shock cognate 71 kDa protein	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to activity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
synaptic vesicle uncoating	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cerebellum development	Heat shock cognate 71 kDa protein	Homo sapiens (human)
forebrain development	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of protein stability	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to estradiol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to progesterone	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cellular response to heat	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein refolding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of protein-containing complex assembly	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein transmembrane import into intracellular organelle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation by host of viral genome replication	Heat shock cognate 71 kDa protein	Homo sapiens (human)
estrous cycle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to ethanol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of proteolysis	Heat shock cognate 71 kDa protein	Homo sapiens (human)
negative regulation of DNA-templated transcription	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ATP metabolic process	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of phagocytosis	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of cell cycle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
membrane organization	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of protein complex stability	Heat shock cognate 71 kDa protein	Homo sapiens (human)
chaperone-mediated autophagy	Heat shock cognate 71 kDa protein	Homo sapiens (human)
late endosomal microautophagy	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein targeting to lysosome involved in chaperone-mediated autophagy	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cellular response to hydrogen peroxide	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cellular response to cadmium ion	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cellular response to steroid hormone stimulus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
clathrin coat disassembly	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of lysosomal membrane permeability	Heat shock cognate 71 kDa protein	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of postsynapse organization	Heat shock cognate 71 kDa protein	Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assembly	Heat shock cognate 71 kDa protein	Homo sapiens (human)
negative regulation of supramolecular fiber organization	Heat shock cognate 71 kDa protein	Homo sapiens (human)
regulation of protein import	Heat shock cognate 71 kDa protein	Homo sapiens (human)
positive regulation of protein refolding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
chaperone-mediated autophagy translocation complex disassembly	Heat shock cognate 71 kDa protein	Homo sapiens (human)
slow axonal transport	Heat shock cognate 71 kDa protein	Homo sapiens (human)
response to odorant	Heat shock cognate 71 kDa protein	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signal	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
tachykinin receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
heart development	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
viral genome replication	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
receptor internalization	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
positive regulation of catecholamine secretion	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of striated muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
symbiont entry into host cell	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cardiac muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of relaxation of smooth muscle	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
regulation of the force of heart contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
purine ribonucleoside salvage	Adenosine kinase	Homo sapiens (human)
dATP biosynthetic process	Adenosine kinase	Homo sapiens (human)
ribonucleoside monophosphate biosynthetic process	Adenosine kinase	Homo sapiens (human)
GMP salvage	Adenosine kinase	Homo sapiens (human)
AMP salvage	Adenosine kinase	Homo sapiens (human)
dAMP salvage	Adenosine kinase	Homo sapiens (human)
purine nucleobase metabolic process	Adenosine kinase	Homo sapiens (human)
visual perception	Rhodopsin kinase GRK1	Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathway	Rhodopsin kinase GRK1	Homo sapiens (human)
rhodopsin mediated signaling pathway	Rhodopsin kinase GRK1	Homo sapiens (human)
regulation of opsin-mediated signaling pathway	Rhodopsin kinase GRK1	Homo sapiens (human)
protein autophosphorylation	Rhodopsin kinase GRK1	Homo sapiens (human)
protein phosphorylation	Rhodopsin kinase GRK1	Homo sapiens (human)
regulation of signal transduction	Rhodopsin kinase GRK1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
gene expression	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
heterochromatin formation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
telomere organization	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
methylation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
regulation of transcription regulatory region DNA binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA repair	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA damage checkpoint signaling	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
phosphatidylserine binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
RNA binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ATP binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ATP hydrolysis activity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
enzyme binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
MHC class II protein complex binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein-macromolecule adaptor activity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
heat shock protein binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
A1 adenosine receptor binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
peptide binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ADP binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cadherin binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
unfolded protein binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein-folding chaperone binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
C3HC4-type RING finger domain binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ATP-dependent protein disaggregase activity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein carrier chaperone	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock cognate 71 kDa protein	Homo sapiens (human)
prostaglandin binding	Heat shock cognate 71 kDa protein	Homo sapiens (human)
clathrin-uncoating ATPase activity	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein folding chaperone	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
ATP binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
beta-adrenergic receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
RNA binding	Adenosine kinase	Homo sapiens (human)
deoxyadenosine kinase activity	Adenosine kinase	Homo sapiens (human)
ATP binding	Adenosine kinase	Homo sapiens (human)
metal ion binding	Adenosine kinase	Homo sapiens (human)
adenosine kinase activity	Adenosine kinase	Homo sapiens (human)
protein kinase activity	Rhodopsin kinase GRK1	Homo sapiens (human)
ATP binding	Rhodopsin kinase GRK1	Homo sapiens (human)
rhodopsin kinase activity	Rhodopsin kinase GRK1	Homo sapiens (human)
nucleic acid binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3 methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3K79 trimethyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3K79 methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
lysosomal membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
Prp19 complex	Heat shock cognate 71 kDa protein	Homo sapiens (human)
photoreceptor inner segment	Heat shock cognate 71 kDa protein	Homo sapiens (human)
extracellular region	Heat shock cognate 71 kDa protein	Homo sapiens (human)
extracellular space	Heat shock cognate 71 kDa protein	Homo sapiens (human)
nucleus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
nucleoplasm	Heat shock cognate 71 kDa protein	Homo sapiens (human)
spliceosomal complex	Heat shock cognate 71 kDa protein	Homo sapiens (human)
nucleolus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
lysosomal membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
late endosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
autophagosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cytosol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
microtubule	Heat shock cognate 71 kDa protein	Homo sapiens (human)
intermediate filament	Heat shock cognate 71 kDa protein	Homo sapiens (human)
plasma membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
focal adhesion	Heat shock cognate 71 kDa protein	Homo sapiens (human)
synaptic vesicle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cell surface	Heat shock cognate 71 kDa protein	Homo sapiens (human)
postsynaptic density	Heat shock cognate 71 kDa protein	Homo sapiens (human)
membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
secretory granule lumen	Heat shock cognate 71 kDa protein	Homo sapiens (human)
melanosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
terminal bouton	Heat shock cognate 71 kDa protein	Homo sapiens (human)
dendritic spine	Heat shock cognate 71 kDa protein	Homo sapiens (human)
dendritic shaft	Heat shock cognate 71 kDa protein	Homo sapiens (human)
lysosomal lumen	Heat shock cognate 71 kDa protein	Homo sapiens (human)
perikaryon	Heat shock cognate 71 kDa protein	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock cognate 71 kDa protein	Homo sapiens (human)
clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
extracellular exosome	Heat shock cognate 71 kDa protein	Homo sapiens (human)
blood microparticle	Heat shock cognate 71 kDa protein	Homo sapiens (human)
lumenal side of lysosomal membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
photoreceptor ribbon synapse	Heat shock cognate 71 kDa protein	Homo sapiens (human)
glycinergic synapse	Heat shock cognate 71 kDa protein	Homo sapiens (human)
glutamatergic synapse	Heat shock cognate 71 kDa protein	Homo sapiens (human)
presynaptic cytosol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
postsynaptic cytosol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
postsynaptic specialization membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock cognate 71 kDa protein	Homo sapiens (human)
lysosomal matrix	Heat shock cognate 71 kDa protein	Homo sapiens (human)
protein folding chaperone complex	Heat shock cognate 71 kDa protein	Homo sapiens (human)
ribonucleoprotein complex	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cytosol	Heat shock cognate 71 kDa protein	Homo sapiens (human)
plasma membrane	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cytoplasm	Heat shock cognate 71 kDa protein	Homo sapiens (human)
nucleus	Heat shock cognate 71 kDa protein	Homo sapiens (human)
cytoplasm	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cytosol	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
plasma membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cilium	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
presynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
postsynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
nucleoplasm	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
plasma membrane	Adenosine kinase	Homo sapiens (human)
nucleus	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
photoreceptor disc membrane	Rhodopsin kinase GRK1	Homo sapiens (human)
cytoplasm	Rhodopsin kinase GRK1	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
cytoplasm	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
intracellular membrane-bounded organelle	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
protein-containing complex	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (159)

Assay ID	Title	Year	Journal	Article
AID357078	Inhibition of nuclear protein kinase 2	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1578771	Antimalarial activity against Plasmodium falciparum FCQ-27 isolate infected in erythrocytes assessed as reduction in [G-3H]Hypoxanthine incorporation incubated for 24 hrs followed by addition of [G-3H]Hypoxanthine and measured after 18 to 20 hrs by scinti	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID356856	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as annexin V binding to phosphatidylserine at 0.3 uM after 6 hrs	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356842	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at S phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357064	Inhibition of induction of Bcl-x/s phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID217836	Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID357069	Effect on mitochondrial localization of phosphorylated JNK with Bcl-x/l in human multidrug resistant MCF/ADR cells assessed as enhanced JNK activity by Mitotracker red staining	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356885	Inhibition of induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as inhibition of cleavage of lamin A at 0.3 uM after 48 hrs by immunoblot analysis in presence of caspase 9-specific inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356854	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at S phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1310291	Binding affinity to human truncated HSC70 NBD (1 to 381 residues) by SPR analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.
AID356848	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID82054	Cytotoxicity against HFF cells, estimated by visual scoring of cells not affected by virus infection in the plaque reduction assay	1996	Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4	Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID357052	Reduction in induction of c-Jun phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356851	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G2/M phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID97665	Tested in vitro for antiproliferative activity against growth rate of L1210 cells.(delayed growth inhibition)	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID356862	Increase in p21CIP accumulation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357061	Reduction in induction of c-Jun phosphorylation in human multidrug resistant MCF/ADR cells transfected with c-Jun siRNA at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1578780	Antimalarial activity against Plasmodium falciparum	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID356850	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at S phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID96382	Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID356827	Cytocidal effect in human multidrug resistant MCF/ADR cells assessed as decrease in number of viable cells at 0.1 uM after 1 hr measured after 72 hrs in absence of drug by MTT colorimetric assay	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357053	Inhibition of induction of JNK phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunocytochemical analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID199168	Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID357065	Inhibition of induction of Bcl-x/s phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs in presence of SP600125	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356889	Induction of c-Jun serine 73 phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357058	Reduction in induction of apoptosis in SP600125 pretreated human multidrug resistant MCF/ADR cells assessed as reduction of cleavage of PARP at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357063	Reduction of PPAR cleavage in human multidrug resistant MCF/ADR cells transfected with c-Jun siRNA at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356859	Decrease in p53 accumulation in human multidrug resistant MCF/ADR cells at 0.3 uM after 72 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356879	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as activation of caspase 9 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356841	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G0/G1 phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID54506	Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356874	Induction of apoptosis in human multidrug resistant MDA-MB-468 cells assessed as accumulation of PARP at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID79951	Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV)	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID357074	Inhibition of rhodopsin kinase	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID229059	Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID357122	Induction of c-Jun phosphorylation in human drug-sensitive MCF/WT cells at 0.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID42129	Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID34006	Concentration required for 50% inhibition of the adenosine kinase (AK) activity.	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	A TOPS-MODE approach to predict adenosine kinase inhibition.
AID357062	Reduction of lamin A cleavage in human multidrug resistant MCF/ADR cells transfected with c-Jun siRNA at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID98334	In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID82422	Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID229022	Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID356836	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID229232	Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID82404	Cytotoxicity was evaluated against the Human diploid cells (HFF)	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID357073	Inhibition of PKC	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356869	Increase in Bax levels in human multidrug resistant MCF/ADR cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID224918	Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID356876	Induction of apoptosis in human MCF10A cells assessed as accumulation of PARP at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357068	Induction of JNK activity in human multidrug resistant MCF/ADR cells assessed as mitochondrial localization of phosphorylated JNK with Bcl-x/l	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1596006	Inhibition of wild-type N-terminal TEV cleavage site-fused/His-tagged Mycobacterium tuberculosis H37Rv adenosine kinase expressed in Escherichia coli BL21 (DE3) using adenosine as substrate in presence of ATP and PEP by pyruvate kinase-lactate dehydrogena	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.
AID217479	Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356832	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356863	Increase in Bcl-x/l levels in human drug-sensitive MCF/WT cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356875	Induction of apoptosis in human multidrug resistant MDA-MB-231 cells assessed as accumulation of PARP at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356872	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as accumulation of PARP at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID87203	Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay.	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID356858	Induction of apoptosis in human drug sensitive MCF/WT cells assessed as propidium iodide binding to phosphatidylserine at 0.3 uM after 6 hrs	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356887	Induction of JNK p54 isoform phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356871	Induction of apoptosis in human drug-sensitive MCF/WT cells assessed as cleavage of lamin A at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356833	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G0/G1 phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356828	Cytostatic effect in human drug sensitive MCF/WT cells assessed as slight increase in number of viable cells at 0.1 uM after 1 hr measured after 72 hrs in absence of drug by MTT colorimetric assay	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356857	Induction of apoptosis in human drug sensitive MCF/WT cells assessed as annexin V binding to phosphatidylserine at 0.3 uM after 6 hrs	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID33990	Inhibition of human adenosine kinase activity	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
AID218065	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID357071	Reduction in induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as suppression of lamin A cleavage at 0.3 uM after 48 hrs by immunoblot analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356884	Inhibition of induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as inhibition of cleavage of PARP at 0.3 uM after 48 hrs by immunoblot analysis in presence of pan-specific inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357079	Induction of c-Jun expression in human multidrug resistant MCF/ADR cells at 0.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356861	Increase in p21CIP accumulation in human drug-sensitive MCF/WT cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID33985	Inhibition of recombinant human adenosine kinase	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.
AID356844	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356829	Cytocidal effect in human multidrug resistant MCF/ADR cells assessed as decrease in number of viable cells at 30 nM after 6 days by MTT colorimetric assay	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID97415	Increase in life span for drug treated L1210-bearing mice at the dose of 0.25 mg/kg upon intraperitoneal administration	1983	Journal of medicinal chemistry, Jan, Volume: 26, Issue:1	Pyrrolopyrimidine nucleosides. 18. Synthesis and chemotherapeutic activity of 4-amino-7-(3-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-carboxamide (3'-deoxysangivamycin) and 4-amino-7-(2-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-ca
AID357076	Inhibition of beta-adrenergic receptor kinase	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID84611	Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID220038	Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID357059	Reduction in induction of c-Jun expression in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis in presence of caspase 9 inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356881	Induction of apoptosis in human drug-sensitive MCF/WT cells assessed as activation of caspase 7 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357055	Reduction in induction of phosphorylated form of c-Jun in SP600125 pretreated human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356855	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G2/M phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID90773	Antiviral activity against Human Cytomegalovirus (HCMV) replication in a plaque reduction assay	1996	Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4	Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID356890	Induction of c-Jun serine 63 phosphorylation in human multidrug resistant MCF/ADR cells at 0.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357066	Blockade of apoptosis induction in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357057	Reduction in induction of apoptosis in SP600125 pretreated human multidrug resistant MCF/ADR cells assessed as reduction of cleavage of lamin A at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356886	Inhibition of induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as inhibition of cleavage of PARP at 0.3 uM after 48 hrs by immunoblot analysis in presence of caspase 9-specific inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID96660	Dose required to inhibit proliferation of L-1210 Cells by 50%	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID357075	Inhibition of PKA	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356830	Cytostatic effect in human drug sensitive MCF/WT cells assessed as slight increase in number of viable cells at 30 nM after 6 days by MTT colorimetric assay	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357070	Reduction in induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as suppression of caspase 9 activation at 0.3 uM after 48 hrs by immunoblot analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID85570	Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356853	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G0/G1 phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356839	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G2/M phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357054	Induction of JNK phosphorylation in human multidrug resistant MCF/ADR cells transfected with PKCdelta siRNA at 0.3 uM after 48 hrs by immunocytochemical analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356847	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G2/M phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1636908	Inhibition of DOT1L (unknown origin) using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
AID96800	In vitro concentration required to reduce the growth rate of murine leukemia L1210 to 50% of the control	1983	Journal of medicinal chemistry, Jan, Volume: 26, Issue:1	Pyrrolopyrimidine nucleosides. 18. Synthesis and chemotherapeutic activity of 4-amino-7-(3-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-carboxamide (3'-deoxysangivamycin) and 4-amino-7-(2-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-ca
AID90794	Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay.	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID356864	Increase in Bcl-x/l levels in human multidrug resistant MCF/ADR cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356867	Increase in Bcl-2 levels in human drug-sensitive MCF/WT cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID96608	Inhibition of murine leukemia L1210 cell growth	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356860	Increase in wild-type full length p53 accumulation in human drug-sensitive MCF/WT cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID155586	Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID33993	Inhibition concentration against human adenosine kinase	2002	Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6	QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
AID356865	Increase in Bcl-x/s levels in human drug-sensitive MCF/WT cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357077	Inhibition of nuclear protein kinase 1	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1296048	Induction of phenotypic perturbation in human ONS cells assessed as decrease in EEA1-associated early endosomes level in at 10 uM after 24 hrs by EEA1 staining based assay relative to control	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID225769	Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID357080	Induction of c-Jun expression in human drug-sensitive MCF cells at 0.3 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID162251	Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID357072	Reduction in induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as suppression of PARP cleavage at 0.3 uM after 48 hrs by immunoblot analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID382097	Inhibition of adenosine kinase	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	A CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues.
AID356852	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID1296049	Induction of phenotypic perturbation in human ONS cells assessed as decrease in autophagy markers level in at 10 uM after 24 hrs relative to control	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID356835	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G2/M phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356845	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G0/G1 phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID87204	Tested in vitro for antiviral activity against HSV-1 in yield reduction assay.	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID84959	Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID95827	Cytotoxic activity tested against exponentially growing KB cells, determined by staining method	1996	Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4	Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID356877	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as activation of caspase 6 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356840	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at sub G0/G1 phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356826	Cytocidal effect in human multidrug resistant MCF/ADR cells assessed as decrease in number of viable cells at 0.1 uM after 72 hrs by MTT colorimetric assay	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356883	Inhibition of induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as inhibition of cleavage of lamin A at 0.3 uM after 48 hrs by immunoblot analysis in presence of pan-specific inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357060	Reduction in induction of c-Jun expression in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis in presence of pan-specific caspase inhibitor	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID90937	Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay.	1990	Journal of medicinal chemistry, Dec, Volume: 33, Issue:12	Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID96613	Minimum inhibitory concentration required to reduce incorporation of [methyl-3H]dThd into TCA-insoluble material from murine leukemia L1210 cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID167151	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356866	Increase in Bcl-x/s levels in human multidrug resistant MCF/ADR cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356831	Effect on cell morphology in human multidrug resistant MCF/ADR cells assessed as floating cells with intact plasma membrane at 0.3 uM after 72 hrs by trypan blue dye exclusion test	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID87304	Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID356838	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at S phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID217478	Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356849	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at G0/G1 phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID204956	Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356837	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G0/G1 phase at 0.3 uM after 48 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID87798	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID356880	Induction of apoptosis in human drug-sensitive MCF/WT cells assessed as activation of caspase 6 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356888	Induction of JNK p46 isoform phosphorylation in human drug-sensitive MCF/WT cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357067	Blockade of apoptosis induction in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs in presence of SP600125	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID226343	Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID357056	Reduction in induction of non phosphorylated form of c-Jun in SP600125 pretreated human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID220035	Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID83889	Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID167327	Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID356873	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as accumulation of PARP at 0.3 uM after 72 hrs by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID357081	Reduction in induction of c-Jun expression in human multidrug resistant MCF/ADR cells at 0.3 uM after 48 hrs by immunoblot analysis in presence of rottlerin	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356843	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at G2/M phase at 0.3 uM after 72 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID96358	Cytotoxicity was evaluated in Human neoplastic cell line (KB)	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID356846	Cell cycle arrest in human multidrug resistant MCF/ADR cells assessed as accumulation at S phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID98461	Occurrence of drug-induced shortening of life span resulting from treatment at 0.25 mg/kg dose in L1210-bearing mice; y=yes	1983	Journal of medicinal chemistry, Jan, Volume: 26, Issue:1	Pyrrolopyrimidine nucleosides. 18. Synthesis and chemotherapeutic activity of 4-amino-7-(3-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-carboxamide (3'-deoxysangivamycin) and 4-amino-7-(2-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-ca
AID356878	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as activation of caspase 7 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356868	Increase in Bcl-2 levels in human multidrug resistant MCF/ADR cells at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID228410	Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID229230	Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID356882	Induction of apoptosis in human drug-sensitive MCF/WT cells assessed as cleavage of caspase 9 at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356870	Induction of apoptosis in human multidrug resistant MCF/ADR cells assessed as cleavage of lamin A at 0.3 uM by immunoblot analysis	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID356834	Cell cycle arrest in human drug-sensitive MCF/WT cells assessed as accumulation at S phase at 0.3 uM after 24 hrs by propidium fluorescence flow cytometry	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
AID96611	Minimum inhibitory concentration required to reduce incorporation of [4,5-3H]leucine into TCA-insoluble material from murine leukemia L1210 cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2010	The EMBO journal, Oct-06, Volume: 29, Issue:19	Molecular basis for activation of G protein-coupled receptor kinases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	24 (30.00)	18.7374
1990's	24 (30.00)	18.2507
2000's	15 (18.75)	29.6817
2010's	14 (17.50)	24.3611
2020's	3 (3.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.22%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	81 (98.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

nsc 65346

Description

Cross-References

Synonyms (41)

Roles (1)

Drug Classes (1)

Pathways (1)

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Biological Processes (91)

Molecular Functions (40)

Ceullar Components (50)

Bioassays (159)

Research

Studies (80)

Study Types

Research Highlights

Safety/Toxicity (4)

Condition	Relationship Strength	Studies
2019 Novel Coronavirus Disease	low	2
2019 Novel Coronavirus Infection	low	2
2019-nCoV Disease	low	2
2019-nCoV Infection	low	2
Absence Seizure	low	1
Absence Seizures	low	1
Angiogenesis, Pathologic	low	1
Angiogenesis, Pathological	low	1
Atonic Absence Seizure	low	1
Atonic Absence Seizures	low	1
Atonic Seizure	low	1
Atonic Seizures	low	1
Babesia Infection	low	1
Babesia Parasite Infection	low	1
Babesiasis	low	1
Babesiosis	low	1
Bovine Diseases	low	1
Breast Cancer	low	2
Breast Carcinoma	low	2
Breast Neoplasms	low	2
Breast Tumors	low	2
Cancer of Breast	low	2
Cancer of Colon	low	4
Cancer of Lung	low	1
Cancer of Pancreas	low	1
Cancer of the Breast	low	2
Cancer of the Colon	low	4
Cancer of the Lung	low	1
Cancer of the Pancreas	low	1
Carcinoma, Ehrlich Tumor	low	2
Cattle Diseases	low	1
Chromosomal Translocation	low	1
Clonic Seizure	low	1
Clonic Seizures	low	1
Colon Cancer	low	4
Colon Neoplasms	low	4
Colonic Cancer	low	4
Colonic Neoplasms	low	4
Complex Partial Seizure	low	1
Complex Partial Seizures	low	1
Convulsion	low	1
Convulsion, Non-Epileptic	low	1
Convulsions	low	1
Convulsive Seizure	low	1
Convulsive Seizures	low	1
Coronavirus Disease 2019	low	2
Coronavirus Disease-19	low	2
COVID-19	low	2
COVID-19 Pandemic	low	2
COVID-19 Pandemics	low	2
COVID-19 Virus Disease	low	2
COVID-19 Virus Infection	low	2
COVID19	low	2
Cytomegalic Inclusion Disease	low	2
Cytomegalovirus	low	6
Cytomegalovirus Infections	low	2
Ebola Hemorrhagic Fever	low	1
Ebola Infection	low	1
Ebola Virus Disease	low	1
Ebola Virus Infection	low	1
Ebolavirus Infection	low	1
Ehrlich Ascites Tumor	low	2
EHS Tumor	low	1
Epileptic Seizure	low	1
Epileptic Seizures	low	1
Experimental Leukemia	low	1
Experimental Leukemias	low	1
Experimental Neoplasms	low	1
Experimental Sarcoma	low	1
Experimental Sarcomas	low	1
Furrow Keratitis	low	1
Generalized Absence Seizure	low	1
Generalized Absence Seizures	low	1
Generalized Tonic-Clonic Seizures	low	1
Granulocytic Leukemia	low	1
Hemorrhagic Fever, Ebola	low	1
Herpes Simplex	low	1
Herpes Simplex Virus Infection	low	1
HIV	low	1
Human Babesiosis	low	1
Human Mammary Carcinoma	low	2
Idiopathic Parkinson Disease	low	1
Idiopathic Parkinson's Disease	low	1
Inclusion Disease	low	2
Infections, Cytomegalovirus	low	2
Infections, Plasmodium	low	2
Jacksonian Seizure	low	1
Kahler Disease	low	1
Keratitis, Dendritic	low	1
Keratitis, Furrow	low	1
Leukemia L 1210	low	4
Leukemia L1210	low	4
Leukemia Model, Animal	low	1
Leukemia, Experimental	low	1
Leukemia, Granulocytic	low	1
Leukemia, Monocytic, Chronic	low	1
Leukemia, Myelocytic	low	1
Leukemia, Myelogenous	low	1
Leukemia, Myeloid	low	1
Leukemias, Experimental	low	1
Lewy Body Parkinson Disease	low	1
Lewy Body Parkinson's Disease	low	1
Lung Cancer	low	1
Lung Neoplasms	low	1
Lymphoma, Primary Effusion	low	2
Malaria	low	2
Malaria, Falciparum	low	1
Malignant Neoplasm of Breast	low	2
Malignant Tumor of Breast	low	2
Mammary Cancer	low	2
Mammary Carcinoma, Human	low	2
Mammary Neoplasm, Human	low	2
Mammary Neoplasms, Human	low	2
Marsh Fever	low	2
Monocytic Leukemia, Chronic	low	1
Morphine Abuse	low	1
Morphine Addiction	low	1
Morphine Dependence	low	1
Multiple Myeloma	low	1
Myelocytic Leukemia	low	1
Myelogenous Leukemia	low	1
Myeloid Leukemia	low	1
Myeloma-Multiple	low	1
Myeloma, Multiple	low	1
Myeloma, Plasma-Cell	low	1
Myelomatosis	low	1
Myoclonic Seizure	low	1
Myoclonic Seizures	low	1
Neoplasms, Breast	low	2
Neoplasms, Colonic	low	4
Neoplasms, Experimental	low	1
Neoplasms, Lung	low	1
Neoplasms, Pancreatic	low	1
Neoplasms, Pulmonary	low	1
Neovascularization, Pathologic	low	1
Neovascularization, Pathological	low	1
Non-Epileptic Seizure	low	1
Non-Epileptic Seizures	low	1
Nonepileptic Seizure	low	1
Nonepileptic Seizures	low	1
Paludism	low	2
Pancreas Cancer	low	1
Pancreas Neoplasms	low	1
Pancreatic Cancer	low	1
Pancreatic Neoplasms	low	1
Paralysis Agitans	low	1
Parkinson Disease	low	1
Parkinson Disease, Idiopathic	low	1
Parkinson's Disease	low	1
Parkinson's Disease, Idiopathic	low	1
Parkinson's Disease, Lewy Body	low	1
Partial Seizure	low	1
Partial Seizures	low	1
Pathologic Angiogenesis	low	1
Pathologic Neovascularization	low	1
Petit Mal Convulsion	low	1
Piroplasmosis	low	1
Plasma Cell Myeloma	low	1
Plasmodium falciparum Malaria	low	1
Plasmodium Infections	low	2
Primary Effusion Lymphoma	low	2
Primary Parkinsonism	low	1
Pulmonary Cancer	low	1
Pulmonary Neoplasms	low	1
Remittent Fever	low	2
Salivary Gland Virus Disease	low	2
Sarcoma 180	low	2
Sarcoma 180, Crocker	low	2
Sarcoma, Engelbreth-Holm-Swarm	low	1
Sarcoma, Experimental	low	1
Sarcoma, Jensen	low	1
Sarcomas, Experimental	low	1
SARS Coronavirus 2 Infection	low	2
SARS-CoV-2 Infection	low	2
Seizure	low	1
Seizures	low	1
Seizures, Auditory	low	1
Seizures, Clonic	low	1
Seizures, Convulsive	low	1
Seizures, Epileptic	low	1
Seizures, Focal	low	1
Seizures, Generalized	low	1
Seizures, Gustatory	low	1
Seizures, Motor	low	1
Seizures, Olfactory	low	1
Seizures, Sensory	low	1
Seizures, Somatosensory	low	1
Seizures, Tonic	low	1
Seizures, Tonic-Clonic	low	1
Seizures, Vertiginous	low	1
Seizures, Vestibular	low	1
Seizures, Visual	low	1
Single Seizure	low	1
Tonic Clonic Seizure	low	1
Tonic Seizure	low	1
Tonic Seizures	low	1
Tonic-Clonic Seizure	low	1
Tonic-Clonic Seizures	low	1
Translocation, Chromosomal	low	1
Translocation, Genetic	low	1
Tumors, Breast	low	2

Article	Year
Sulforaphane Exhibits Cytotoxic Effects against Primary Effusion Lymphoma Cells by Suppressing p38MAPK and AKT Phosphorylation. Biological & pharmaceutical bulletin, Volume: 42, Issue: 12	2019
The antiherpesvirus activity and cytotoxicity of sangivamycin. Current eye research, Volume: 6, Issue: 1	1987
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. Journal of medicinal chemistry, Volume: 32, Issue: 2	1989
Synthesis, cytotoxicity, and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. Journal of medicinal chemistry, Volume: 32, Issue: 7	1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
toyocamycin	[no description available]	medium	31	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
acyclovir	[no description available]	medium	3	2-aminopurines; oxopurine	antimetabolite; antiviral drug
ganciclovir	[no description available]	medium	3	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
tubercidin	[no description available]	medium	13	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
ribavirin	[no description available]	medium	2	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
formycin	[no description available]	medium	2	formycin	antineoplastic agent
2'-deoxytubercidin	[no description available]	medium	1	deoxyribonucleoside; N-glycosylpyrrolopyrimidine
bromotubercidin	[no description available]	medium	5
5-iodotubercidin	[no description available]	medium	8	organoiodine compound
5-chlorotubercidin	[no description available]	medium	5
5'-deoxytoyocamycin	[no description available]	medium	4
5'-amino-5'-deoxyadenosine	[no description available]	medium	2
quinacrine	[no description available]	medium	1	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
chlordecone	[no description available]	medium	1	cyclic ketone; organochlorine compound	insecticide; persistent organic pollutant
aminocaproic acid	[no description available]	medium	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
5,6-dimethylbenzimidazole	[no description available]	medium	1	dimethylbenzimidazole	Escherichia coli metabolite; human metabolite
hexachlorocyclohexane	[no description available]	medium	1	chlorocyclohexane
parathion	[no description available]	medium	1	C-nitro compound; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; mouse metabolite
pentachlorophenol	[no description available]	medium	1	aromatic fungicide; chlorophenol; organochlorine pesticide; pentachlorobenzenes	human xenobiotic metabolite
pyrazinamide	[no description available]	medium	1	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
amitrole	[no description available]	medium	1	aromatic amine; triazoles	carotenoid biosynthesis inhibitor; EC 1.11.1.6 (catalase) inhibitor; herbicide
phenytoin	[no description available]	medium	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acebutolol	[no description available]	medium	1	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen	[no description available]	medium	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide	[no description available]	medium	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide	[no description available]	medium	1	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
albuterol	[no description available]	medium	1	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
altretamine	[no description available]	medium	1	triamino-1,3,5-triazine
amantadine	[no description available]	medium	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
ametantrone	[no description available]	medium	1
aminoglutethimide	[no description available]	medium	1	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
theophylline	[no description available]	medium	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
2-aminothiazole	[no description available]	medium	1	1,3-thiazoles; primary amino compound
amlodipine	[no description available]	medium	1	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
aspirin	[no description available]	medium	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol	[no description available]	medium	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine	[no description available]	medium	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azinphosmethyl	[no description available]	medium	1	benzotriazines; organic thiophosphate; organothiophosphate insecticide	agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor
betaxolol	[no description available]	medium	1	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bisoprolol	[no description available]	medium	1	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent

nsc 65346

Description

Cross-References

Synonyms (41)

Roles (1)

Drug Classes (1)

Pathways (1)

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Biological Processes (91)

Molecular Functions (40)

Ceullar Components (50)

Bioassays (159)

Research

Studies (80)

Study Types

Related Drugs (626)

Related Conditions (201)

Research Highlights

Safety/Toxicity (4)